EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC 4.0

Mirikizumab Sustained Impact on Fatigue in Patients with Moderately to Severely Active Crohn’s Disease in the Phase 2 AMAG Study

Miguel Regueiro iD, Monika Fischer, Peter Bossuyt iD, Kim McGinnis, Marijana Protic, Theresa Hunter Gibble iD, Tommaso Panni, Lai Shan Chan, Toshifumi Hibi, David T Rubin

Inflammatory Bowel Diseases · 2025

DOI: 10.1093/ibd/izae166 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Inflammatory Bowel Diseases, 2025. Verfasst von Miguel Regueiro und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Hepatology and Nutrition, Cleveland Clinic, Cleveland, OH, USA. Hauptthemen laut MEDLINE: Crohn Disease, Fatigue, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Fatigue is a burdensome, under-recognized, multidimensional symptom experienced by patients with Crohn’s disease (CD). We evaluated the impact of mirikizumab on fatigue and the association between changes in select patient-reported outcomes and clinical measures with changes in fatigue from baseline to week 104 (W104).

Methods

Patients (N = 191) were randomized (2:1:1:2) to receive placebo (PBO), 200 mg, 600 mg, or 1000 mg of mirikizumab, administered intravenously (IV) every 4 weeks at W0, W4, and W8. Patients who achieved ≥1 point improvement in Simple Endoscopic Score for Crohn’s Disease (SES-CD) and received mirikizumab at W12 (rerandomized maintenance cohort) were rerandomized to continue induction IV treatment assignment (IV-C) or received 300 mg of mirikizumab subcutaneously (SC) until W52. Nonrandomized maintenance cohort had endoscopic nonimprovers (1000 mg) and PBO patients (PBO/1000 mg) who received 1000 mg of mirikizumab until W52. Subjects from the maintenance period with clinical benefit received 300 mg SC Q4W from W52 to W104. The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) questionnaire was used to assess fatigue, and the FACIT-F associations were assessed using Pearson correlation coefficient.

Results

At W12, mirikizumab groups reported improved FACIT-F scores compared with PBO, and improvement was maintained through W52 and W104. Changes in FACIT-F at W52 and W104 had strong correlations with changes at the same time point in quality of life (QoL) scores but lacked correlations with changes in inflammatory biomarkers.

Conclusions

Mirikizumab treatment significantly improved fatigue in patients with moderately to severely active CD, which was sustained to W104. The improvement in fatigue was correlated with improvement in clinical measures and was strongly correlated with improvement in QoL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseFatigueAntibodies, Monoclonal, HumanizedHumansMaleFemaleAdultSeverity of Illness IndexMiddle AgedDouble-Blind MethodPatient Reported Outcome MeasuresQuality of LifeYoung AdultTreatment Outcome

Stichwörter der Autor:innen

Crohn’s diseasefatiguequality of life

Substanzen

Antibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Gastroenterology, Hepatology and Nutrition, Cleveland Clinic, Cleveland, OH, USA.
  • Division of Gastroenterology and Hepatology, Indiana University, Indianapolis, IN, USA.
  • Imelda GI Clinical Research Centre, Imelda General Hospital, Bonheiden, Belgium.
  • Eli Lilly and Company, Indianapolis, IN, USA.
  • Kitasato Institute Hospital Center for Advanced Inflammatory Bowel Disease Research and Treatment, Minato-ku, Tokyo, Japan.
  • Inflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, IL, USA.

ORCID-Profile: Miguel Regueiro, Peter Bossuyt, Theresa Hunter Gibble

Förderung

  • Eli Lilly and Company

Zitieren

APA

Regueiro, M., Fischer, M., Bossuyt, P., McGinnis, K., Protic, M., Hunter Gibble, T., Panni, T., Chan, L. S., Hibi, T., & Rubin, D. T. (2025). Mirikizumab Sustained Impact on Fatigue in Patients with Moderately to Severely Active Crohn’s Disease in the Phase 2 AMAG Study. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izae166

Vancouver

Regueiro M, Fischer M, Bossuyt P, McGinnis K, Protic M, Hunter Gibble T, et al. Mirikizumab Sustained Impact on Fatigue in Patients with Moderately to Severely Active Crohn’s Disease in the Phase 2 AMAG Study. Inflammatory Bowel Diseases. 2025. doi:10.1093/ibd/izae166

BibTeX
@article{Regueiro2025,
  author = {Regueiro, Miguel and Fischer, Monika and Bossuyt, Peter and McGinnis, Kim and Protic, Marijana and Hunter Gibble, Theresa and Panni, Tommaso and Chan, Lai Shan and Hibi, Toshifumi and Rubin, David T},
  title = {Mirikizumab Sustained Impact on Fatigue in Patients with Moderately to Severely Active Crohn’s Disease in the Phase 2 AMAG Study},
  journal = {Inflammatory Bowel Diseases},
  year = {2025},
  doi = {10.1093/ibd/izae166}
}
Kostenlos starten →